febrile neutropenia alone if they are receiving Candida prophylaxis, lack biomarker positivity, and have no clinical signs or imaging abnormalities suggestive of IFI. 13 However, any high-risk patient with a nodular pulmonary infiltrate should be
Search Results
Maxim Norkin and John R. Wingard
Pamala A. Pawloski, Gabriel A. Brooks, Matthew E. Nielsen, and Barbara A. Olson-Bullis
-stimulating factor use without an increase in febrile neutropenia rates, illustrating the positive impact these powerful tools can have on clinical oncology care. 50 Further analyses of the use of these tools with appropriate study designs and analytic methods are
Lindsey Robert Baden, William Bensinger, Michael Angarone, Corey Casper, Erik R. Dubberke, Alison G. Freifeld, Ramiro Garzon, John N. Greene, John P. Greer, James I. Ito, Judith E. Karp, Daniel R. Kaul, Earl King, Emily Mackler, Kieren A. Marr, Jose G. Montoya, Ashley Morris-Engemann, Peter G. Pappas, Ken Rolston, Brahm Segal, Susan K. Seo, Sankar Swaminathan, Maoko Naganuma, and Dorothy A. Shead
controls. 205 , 206 During community outbreaks, influenza infections may represent a significant proportion of episodes of febrile neutropenia. 207 Influenza infections in severely immunocompromised patients with cancer are often associated with
Suzanne C. O'Neill, Claudine Isaacs, Calvin Chao, Huei-Ting Tsai, Chunfu Liu, Bola F. Ekezue, Nandini Selvam, Larry G. Kessler, Marc D. Schwartz, Tania Lobo, and Arnold L. Potosky
. 38. Chia VM Page JH Rodriguez R . Chronic comorbid conditions associated with risk of febrile neutropenia in breast cancer patients treated with chemotherapy . Breast Cancer Res Treat 2013 ; 138 : 621 – 631 . 39. Hall PS McCabe C
Adam J. Olszewski, Kalyan C. Mantripragada, and Jorge J. Castillo
%), red blood cell transfusions (47%), and arrhythmias (4%). Similarly, Delarue et al 4 found an 18% rate of febrile neutropenia and a 4% rate of cardiovascular severe adverse effects, with 13% of all fatalities ascribed to complications of R-CHOP. The
Robert W. Carlson, Susan Moench, Arti Hurria, Lodovico Balducci, Harold J. Burstein, Lori J. Goldstein, William J. Gradishar, Kevin S. Hughes, Mohammad Jahanzeb, Stuart M. Lichtman, Lawrence B. Marks, Joan S. McClure, Beryl McCormick, Lisle M. Nabell, Lori J. Pierce, Mary Lou Smith, Neal S. Topham, Tiffany A. Traina, John H. Ward, and Eric P. Winer
prophylaxis with granulocyte-colony stimulating factors (G-CSF) versus placebo or untreated controls in patients undergoing chemotherapy indicated that G-CSF therapy was associated with decreased incidences of febrile neutropenia and early death, and a higher
Pamela S. Becker
-filgrastim is indicated to reduce the duration of severe neutropenia in patients with nonmyeloid malignancies receiving myelosuppressive chemotherapy drugs associated with a clinically significant incidence of febrile neutropenia. Tbo-filgrastim is approved as a
Shi-Yi Wang, Tiange Chen, Weixiong Dang, Sarah S. Mougalian, Suzanne B. Evans, and Cary P. Gross
), and 25% of all patients treated with chemotherapy would receive granulocyte colony-stimulating factor (G-CSF) pegfilgrastim (on average 2 cycles) for the secondary prevention of febrile neutropenia. 18 For patients who did not receive ODX testing, we
Arti Hurria, Ilene S. Browner, Harvey Jay Cohen, Crystal S. Denlinger, Mollie deShazo, Martine Extermann, Apar Kishor P. Ganti, Jimmie C. Holland, Holly M. Holmes, Mohana B. Karlekar, Nancy L. Keating, June McKoy, Bruno C. Medeiros, Ewa Mrozek, Tracey O’Connor, Stephen H. Petersdorf, Hope S. Rugo, Rebecca A. Silliman, William P. Tew, Louise C. Walter, Alva B. Weir III, and Tanya Wildes
, comorbidities, anthracycline-based regimens, a 28-day schedule, and febrile neutropenia as independent predictors of reduced dose-intensity among patients with early-stage breast cancer undergoing adjuvant chemotherapy. 167 In another retrospective analysis of
Jeffrey A. Gilreath, David D. Stenehjem, and George M. Rodgers
chemotherapy with a high rate of febrile neutropenia. 9 Table 2 displays the benefits and potential risks of parenteral iron administration reported in a variety of patient populations or studied in animal models. Because these risks have not specifically
